Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: ERN, ERP

Avanos Medical, Inc. Announces Second Quarter 2022 Results


ALPHARETTA, Ga., Aug. 9, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2022 financial results.

"Despite ongoing raw material availability and associated supply chain disruptions, underlying demand for our products remains strong," said Joe Woody, Avanos' Chief Executive Officer. Woody continued, "We delivered on expansion of our gross and operating margin, and generated meaningful free cash flow in a tough environment inclusive of inflationary and foreign currency headwinds. We anticipate strong results for the full year despite continued macroeconomic and supply chain challenges."

Second Quarter 2022 Financial Highlights

Operational and Business Highlights

Second Quarter 2022 Operating Results

For the three months ended June 30, 2022, net sales totaled $203 million, an increase of 9 percent compared to the prior year period, primarily due to incremental revenue from the acquisition of OrthogenRx. In addition to volume, 1 percent of favorable pricing was offset by 2 percent of unfavorable foreign currency translation effects.

Gross margin was 57 percent, compared to 46 percent in the prior year period. Adjusted gross margin was 59 percent, compared to 51 percent last year. Gross profit margin improved primarily due to favorable product mix, as well as slightly improved manufacturing efficiencies that were partially offset by higher costs across our supply chain.

Selling and general expenses as a percentage of net sales was 43 percent for the second quarter of 2022, compared to 46 percent for the first quarter of 2022.

Operating profit was $19 million compared to a $7 million operating loss in the prior year period, primarily due to the improved gross margin previously noted as well as lower legal expenses. On an adjusted basis, operating profit totaled $28 million, compared to $15 million a year ago.

Adjusted EBITDA for the second quarter was $33 million, compared to $20 million in the prior year period.

First Six Months 2022 Operating Results

For the six months ended June 30, 2022, net sales were $400 million, an increase of 9 percent compared to the prior year period.  Digestive health products experienced strong demand and volume, which was offset by decreased demand and volume in respiratory health products. In addition to volume, 1 percent of favorable pricing was offset by 1 percent of unfavorable foreign currency translation effects.

Gross margin was 55 percent, compared to 48 percent last year. Adjusted gross margin was 57 percent compared to 52 percent last year and was impacted by the same items noted above for the second quarter.

Operating profit was $28 million, compared to operating loss of $20 million in the prior year period, primarily due to the improved gross margin previously noted as well as lower legal expenses, partially offset by higher selling and general expenses.  On an adjusted basis, operating profit was $46 million compared to $31 million a year ago.

Adjusted EBITDA for the six months ended June 30, 2022 was $57 million compared to $42 million in the prior year period.

Cash Flow and Balance Sheet

Cash from operations less capital expenditures, or free cash flow, for the second quarter was $23 million, compared to $10 million a year ago. The company's cash balance at June 30, 2022 was $107 million, compared to $119 million at year-end 2021.

Total long-term debt outstanding was $254 million at June 30, 2022, compared to $130 million at December 31, 2021. In the first quarter of 2022, the company borrowed $125 million in conjunction with closing the acquisition of OrthogenRx.

Full-Year 2022 Outlook

The company is modifying its guidance for 2022 net sales to between $815 million and $835 million, which assumes organic growth between 1 percent to 4 percent. Additionally, we are confirming gross profit margins to be between 55 percent to 57 percent, with adjusted diluted earnings per share between $1.45 and $1.65.

Each of these measures is inclusive of the impact of the OrthogenRx acquisition and reflects our expectation that supply chain headwinds related to both product availability and inflationary pressures will continue throughout the year.

Non-GAAP Financial Measures

This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:

These non-GAAP financial measures exclude the following items, as applicable, for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:

The company provides these non-GAAP financial measures as supplemental information to its GAAP financial measures. Management and the company's Board of Directors use net sales on a constant currency basis, adjusted net income, adjusted diluted earnings per share, adjusted operating profit, adjusted EBITDA, and free cash flow to: (a) evaluate the company's historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the company's business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of the company's ongoing business operations.

Additionally, the Compensation Committee of the company's Board of Directors will use certain of the non-GAAP financial measures when setting and assessing achievement of incentive compensation goals. These goals are based, in part, on the company's net sales on a constant currency basis and adjusted EBITDA, which will be determined by excluding certain items that are used in calculating these non-GAAP financial measures.

Our competitors may define these non-GAAP financial measures differently, and as a result, our measure of these non-GAAP financial measures may not be directly comparable to those of other companies. Items excluded from these non-GAAP financial measures are significant components in understanding and assessing financial performance. These non-GAAP financial measures are supplemental measures of operating performance that do not represent, and should not be considered in isolation or as an alternative to, or substitute for, the financial statement data presented in the company's consolidated financial statements as indicators of financial performance. These non-GAAP financial measures have limitations as analytical tools, and should not be considered in isolation, or as a substitute for analysis of the company's results as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP results and using these non-GAAP financial measures as supplemental information.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the attached financial tables.

Conference Call Webcast

Avanos Medical, Inc. will host a conference call today at 9 a.m. ET. The conference call can be accessed live over the Internet at https://avanos.investorroom.com or via telephone by dialing 877-240-5772 in the United States. A replay of the call will be available at noon ET today by calling 877-344-7529 in the United States and entering passcode 8164434. A webcast of the call will also be archived in the Investors section on the Avanos website.

About Avanos Medical, Inc.

Avanos Medical (NYSE: AVNS) is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit www.avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.

Forward-Looking Statements

This press release contains information that includes or is based on "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue" and similar expressions. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; risks related to the ongoing COVID-19 pandemic; shortage in drugs used in our Acute Pain products or other disruptions in our supply chain; the ongoing conflict between Russia and Ukraine; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the impact of investigative and legal proceedings and compliance risks; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; and changes in the competitive environment. Additional information concerning these and other factors that may impact future results is contained in our filings with the U.S. Securities and Exchange Commission, including our most recent Form 10-Q.

 

AVANOS MEDICAL, INC.

CONDENSED CONSOLIDATED INCOME STATEMENTS

(unaudited)

(in millions, except per share amounts)



Three Months Ended June 30,


Six Months Ended June 30,


2022


2021


2022


2021

Net Sales

$                203.0


$                186.4


$                400.4


$                367.1

Cost of products sold

88.1


100.7


178.3


190.1

Gross Profit

114.9


85.7


222.1


177.0

Research and development expenses

8.0


8.0


15.8


16.3

Selling and general expenses

87.1


76.7


177.2


150.1

Other expense, net

0.8


8.3


0.9


30.3

Operating Income (Loss)

19.0


(7.3)


28.2


(19.7)

Interest income

0.2


?


0.2


?

Interest expense

(2.7)


(0.9)


(4.0)


(1.7)

Income (Loss) Before Income Taxes

16.5


(8.2)


24.4


(21.4)

Income tax (provision) benefit

(5.1)


46.1


(7.2)


51.7

Net Income

$                  11.4


$                  37.9


$                  17.2


$                  30.3









Interest expense, net

$                    2.5


$                    0.9


$                    3.8


$                    1.7

Income tax provision (benefit)

5.1


(46.1)


7.2


(51.7)

Depreciation and amortization

11.6


9.5


22.7


19.2

EBITDA

$                  30.6


$                    2.2


$                  50.9


$                   (0.5)









Earnings Per Share








Basic

$                  0.24


$                  0.79


$                  0.36


$                  0.63

Diluted

0.24


0.78


0.36


0.62









Common Shares Outstanding








Basic

47.2


48.1


47.3


48.0

Diluted

47.6


48.6


47.7


48.6

 

AVANOS MEDICAL, INC.

NON-GAAP RECONCILIATIONS

(unaudited)

(in millions)



Gross Profit


Three Months Ended June 30,


Six Months Ended June 30,


2022


2021


2022


2021

As reported

$           114.9


$              85.7


$           222.1


$            177.0

2020 Restructuring charges

?


2.8


?


3.0

Post divestiture restructuring charges

?


1.7


?


2.6

Post divestiture transition charges

?


3.7


?


3.8

Acquisition and integration-related charges

0.7


?


1.4


?

Intangibles amortization

3.5


1.7


6.6


3.3

As adjusted non-GAAP

$           119.1


$              95.6


$           230.1


$            189.7

Gross profit margin, as reported

56.6 %


46.0 %


55.5 %


48.2 %

Gross profit margin, as adjusted

58.7 %


51.3 %


57.5 %


51.7 %

 


Operating Profit (Loss)


Three Months Ended June 30,


Six Months Ended June 30,


2022


2021


2022


2021

As reported

$                  19.0


$                  (7.3)


$                  28.2


$                (19.7)

COVID-19 related expenses

?


0.2


?


0.2

2020 Restructuring charges

?


8.5


?


8.7

Post divestiture restructuring charges

?


1.7


?


2.6

Post divestiture transition charges

?


3.6


?


3.6

Acquisition and integration-related charges

1.0


0.2


2.8


0.6

EU MDR Compliance (a)

1.7


1.0


3.2


1.2

Litigation and legal

?


2.7


?


25.2

Intangibles amortization

6.2


4.1


11.9


8.3

As adjusted non-GAAP

$                  27.9


$                  14.7


$                  46.1


$                  30.7

 





(a)

EU MDR Compliance related charges are included in "Selling and general expenses".

 

AVANOS MEDICAL, INC.

NON-GAAP RECONCILIATIONS

(unaudited)



Income (Loss) Before Taxes


Three Months Ended June 30,


Six Months Ended June 30,


2022


2021


2022


2021

As reported

$                  16.5


$                  (8.2)


$                  24.4


$                (21.4)

COVID-19 related expenses

?


0.2


?


0.2

2020 Restructuring charges

?


8.5


?


8.7

Post divestiture restructuring charges

?


1.7


?


2.6

Post divestiture transition charges

?


3.6


?


3.6

Acquisition and integration-related charges

1.0


0.2


2.8


0.6

EU MDR Compliance

1.7


1.0


3.2


1.2

Litigation and legal

?


2.7


?


25.2

Intangibles amortization

6.2


4.1


11.9


8.3

Loss on extinguishment of debt

1.1


?


1.1


?

As adjusted non-GAAP

$                  26.5


$                  13.8


$                  43.4


$                  29.0

 


Tax Benefit (Provision)


Three Months Ended June 30,


Six Months Ended June 30,


2022


2021


2022


2021

As reported

$              (5.1)


$              46.1


$              (7.2)


$              51.7

Tax effects of adjusting items

(2.0)


(47.1)


(4.5)


(57.0)

Effects of the CARES Act and other

?


(2.7)


?


(2.5)

As adjusted non-GAAP

$              (7.1)


$               (3.7)


$            (11.7)


$               (7.8)

Effective tax rate, as reported

30.9 %


(562.2) %


29.5 %


(241.6) %

Effective tax rate, as adjusted

26.8 %


26.8 %


27.0 %


26.9 %

 

AVANOS MEDICAL, INC.

NON-GAAP RECONCILIATIONS

(unaudited)

(in millions, except per share amounts)



Net Income (Loss)


Three Months Ended June 30,


Six Months Ended June 30,


2022


2021


2022


2021

As reported

$                  11.4


$                  37.9


$                  17.2


$                  30.3

COVID-19 related expenses

?


0.2


?


0.2

2020 Restructuring charges

?


8.5


?


8.7

Post divestiture restructuring charges

?


1.7


?


2.6

Post divestiture transition charges

?


3.6


?


3.6

Acquisition and integration-related charges

1.0


0.2


2.8


0.6

EU MDR Compliance

1.7


1.0


3.2


1.2

Litigation and legal

?


2.7


?


25.2

Intangibles amortization

6.2


4.1


11.9


8.3

Loss on extinguishment of debt

1.1


?


1.1


?

Tax effects of adjusting items

(2.0)


(47.1)


(4.5)


(57.0)

Tax effects of the CARES Act and other

?


(2.7)


?


(2.5)

As adjusted non-GAAP

$                  19.4


$                  10.1


$                  31.7


$                  21.2

Diluted EPS, as reported

$                  0.24


$                  0.78


$                  0.36


$                  0.62

Diluted EPS, as adjusted

$                  0.41


$                  0.21


$                  0.66


$                  0.44

 


EBITDA


Three Months Ended June 30,


Six Months Ended June 30,


2022


2021


2022


2021

EBITDA, as reported

$                  30.6


$                    2.2


$                  50.9


$                  (0.5)

COVID-19 related expenses

?


0.2


?


0.2

2020 Restructuring charges

?


8.5


?


8.7

Post divestiture restructuring charges

?


1.7


?


2.6

Post divestiture transition charges

?


3.6


?


3.6

Acquisition and integration-related charges

1.0


0.2


2.8


0.6

EU MDR Compliance

1.7


1.0


3.2


1.2

Litigation and legal

?


2.7


?


25.2

Adjusted EBITDA

$                  33.3


$                  20.1


$                  56.9


$                  41.6

 

AVANOS MEDICAL, INC.

NON-GAAP RECONCILIATIONS

(unaudited)

(in millions)



Free Cash Flow


Three Months Ended June 30,


Six Months Ended June 30,


2022


2021


2022


2021

Cash provided by operating activities

$                  27.0


$                  15.3


$                  28.8


$                  12.0

Capital expenditures

(4.1)


(5.8)


(9.1)


(11.5)

Free Cash Flow

$                  22.9


$                    9.5


$                  19.7


$                    0.5

 

2022 OUTLOOK



Estimated Range

Diluted earnings per share (GAAP)

$                  0.95

to

$                  1.25

Intangibles amortization

0.25

to

0.25

Other

0.25

to

0.15

Adjusted diluted earnings per share (non-GAAP)

$                  1.45

to

$                  1.65

 

AVANOS MEDICAL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in millions)



June 30,
2022


December 31,
2021

ASSETS




Current Assets




Cash and cash equivalents

$                106.5


$                118.5

Accounts receivable, net

145.4


131.2

Inventories

169.0


150.3

Prepaid and other current assets

16.2


18.6

Total Current Assets

437.1


418.6

Property, Plant and Equipment, net

164.3


168.1

Operating Lease Right-of-Use Assets

33.9


38.6

Goodwill

825.0


801.6

Other Intangible Assets, net

264.9


141.2

Deferred Tax Assets

11.1


10.0

Other Assets

16.5


16.5

TOTAL ASSETS

$            1,752.8


$            1,594.6





LIABILITIES AND STOCKHOLDERS' EQUITY




Current Liabilities




Current portion of long-term debt

$                    4.7


$                     ?

Current portion of operating lease liabilities

13.5


14.7

Trade accounts payable

64.2


56.4

Accrued expenses

68.7


68.1

Total Current Liabilities

151.1


139.2

Long-Term Debt

249.3


130.0

Operating Lease Liabilities

38.4


42.8

Deferred Tax Liabilities

34.7


9.6

Other Long-Term Liabilities

27.7


9.1

TOTAL LIABILITIES

501.2


330.7

Stockholders' Equity

1,251.6


1,263.9

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$            1,752.8


$            1,594.6

 

AVANOS MEDICAL, INC.

CONDENSED CONSOLIDATED CASH FLOW STATEMENTS

(unaudited)

(in millions)



Three Months Ended June 30,


Six Months Ended June 30,


2022


2021


2022


2021

Operating Activities








Net income

$               11.4


$               37.9


$               17.2


$               30.3

Depreciation and amortization

11.6


9.5


22.7


19.2

Net loss on asset dispositions

?


4.8


?


4.9

Changes in operating assets and liabilities, net of acquisition

(0.1)


6.2


(18.6)


3.5

Deferred income taxes and other

4.1


(43.1)


7.5


(45.9)

Cash Provided by Operating Activities

27.0


15.3


28.8


12.0

Investing Activities








Capital expenditures

(4.1)


(5.8)


(9.1)


(11.5)

Acquisition of assets and investments in businesses

?


?


(116.7)


?

Cash Used in Investing Activities

(4.1)


(5.8)


(125.8)


(11.5)

Financing Activities








Proceeds from issuance of secured debt

125.0


?


250.0


?

Secured debt repayments

(125.0)


?


(125.0)


?

Revolving credit facility proceeds

130.0


?


150.0


?

Revolving credit facility repayments

(130.0)


(10.0)


(150.0)


(15.0)

Purchase of treasury stock

(14.7)


(0.5)


(34.1)


(0.5)

Payments of debt issuance costs

(2.3)


?


(2.9)


?

Proceeds from the exercise of stock options

0.1


0.4


0.8


5.2

Cash Provided by (Used in) Financing Activities

(16.9)


(10.1)


88.8


(10.3)

Effect of Exchange Rate Changes on Cash and Cash Equivalents

(3.8)


0.4


(3.8)


(1.8)

Increase (Decrease) in Cash and Cash Equivalents

2.2


(0.2)


(12.0)


(11.6)

Cash and Cash Equivalents - Beginning of Period

104.3


100.1


118.5


111.5

Cash and Cash Equivalents - End of Period

$             106.5


$               99.9


$             106.5


$               99.9

 

AVANOS MEDICAL, INC.

SELECTED BUSINESS AND PRODUCTS DATA

(unaudited)

(in millions)



Three Months Ended June 30,




Six Months Ended June 30,




2022


2021


Change


2022


2021


Change

Chronic Care:












Digestive health

$            80.2


$         79.5


0.9 %


$      161.6


$      157.5


2.6 %

Respiratory health

32.1


36.5


(12.1) %


70.2


79.6


(11.8) %

Total Chronic Care

112.3


116.0


(3.2) %


231.8


237.1


(2.2) %

Pain Management:












Acute pain

$            41.2


$         43.7


(5.7) %


$         79.9


$         80.8


(1.1) %

Interventional pain

49.5


26.7


85.4 %


88.7


49.2


80.3 %

Total Pain Management

90.7


70.4


28.8 %


168.6


130.0


29.7 %

Total Net Sales

$          203.0


$      186.4


8.9 %


$      400.4


$      367.1


9.1 %
















Total


Volume(a)


Pricing/Mix


Currency


Other(b)

Net sales - percentage change

QTD


8.9 %


10.2 %


0.5 %


(1.7) %


(0.1) %

Net sales - percentage change

YTD


9.1 %


9.9 %


0.5 %


(1.4) %


0.1 %

 





(a)

Volume includes incremental sales from acquisitions.

(b)

Other includes rounding.

 

SOURCE Avanos Medical, Inc.


These press releases may also interest you

at 14:05
Law Offices of Howard G. Smith announces an investigation on behalf of Veru Inc. ("Veru" or the "Company") investors concerning the Company's possible violations of federal securities laws. On November 9, 2022, the Pulmonary-Allergy Drugs Advisory...

at 14:05
The "Global Contact Center Interaction Analytics Market, Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report focuses on Contact Center Interaction Analytics market revenue at the global, regional, and company...

at 14:00
According to Arizton's latest research report, the fertilizer spreader market will grow at a CAGR of 4.37% from 2022-2028. Development of smart and autonomous spreaders, increased food consumption & population growth, and fiscal support to farmers...

at 14:00
The 3-month, forward-looking market outlook dropped to a record low, indicating dealers expect a difficult market in months ahead.The economy and interest rates are the top two factors holding back business, putting profits under pressure while costs...

at 14:00
The "Infant Formula Ingredients Global Market Report 2022" report has been added to  ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global...

at 13:48
CB Insights today named Auxa Health to its fourth-annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022....



News published on 9 august 2022 at 07:00 and distributed by: